前沿速览029期| CAR-T治B淋 前沿览新知
01
post-CAR预后指数的开发与验证：一种可用于评估大B细胞淋巴瘤患者在接受≥3线CAR-T细胞疗法后出现疾病进展的预后指数
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment
第一作者：Iacoboni G
J Hematol Oncol (IF=29.5). 2024 Oct 29;17(1):102.
全文网址：https://link.springer.com/content/pdf/10.1186/s13045-024-01608-8.pdf
02
抗生素诱导的肠道微生物组代谢功能下降与CAR-T细胞治疗的临床应答相关
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy
第一作者：Prasad R
Blood (IF=21.0). 2024 Oct 23:blood.2024025366.
全文网址：https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2024025366/518296/Antibiotic-induced-loss-of-gut-microbiome?redirectedFrom=fulltext
03
高级别B细胞淋巴瘤：双打击及其他类型
The high-grade B-cell lymphomas: Double hit and more
第一作者：Davies AJ
Blood (IF=21.0). 2024 Oct 20:blood.2023020780.
全文网址：https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2023020780/518251/The-high-grade-B-cell-lymphomas-Double-hit-and?redirectedFrom=fulltext
04
阻断PSGL-1免疫检查点的抗体可增强T细胞对B细胞淋巴瘤的应答
Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma
第一作者：Pereira JL
Leukemia (IF=12.8). 2024 Oct 25.
全文网址：https://www.nature.com/articles/s41375-024-02446-w
05
整合单细胞多组学的CD19-CAR(+)与CAR(-)T细胞分析可揭示B细胞肿瘤中驱动免疫治疗应答的因素
Integrative single-cell multi-omics of CD19-CAR(pos) and CAR(neg) T cells suggest drivers of immunotherapy response in B cell neoplasias
第一作者：Guerrero-Murillo M
Cell Rep Med (IF=11.7). 2024 Oct 17:101803.
全文网址：https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00550-0?__cf_chl_rt_tk=r.sXL2Zb._lZn7YG.4c6_k5QVRibvyaBjQeRf5jXsSg-1730357792-1.0.1.1-9CgrwFERsoN4qV9ls5.20k6XAaymIQyWw6gIP9oSXSg
06
CD19 CAR-T细胞治疗继发性神经淋巴瘤的毒性和疗效
Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis
第一作者：Kaulen LD
Am J Hematol (IF=10.1). 2024 Oct 23.
全文网址：https://doi.org/10.1002/ajh.27505
07
Tisagenlecleucel回输后出现喉水肿的11例病例：一项CD19 CAR-T细胞治疗复发/难治性B细胞淋巴瘤的3年单中心回顾性研究
Eleven cases of laryngeal edema after tisagenlecleucel infusion: a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas
第一作者：Hosoya E
Haematologica (IF=8.2). 2024 Oct 17.
全文网址：https://haematologica.org/article/view/haematol.2024.286169
08
CAR-T细胞治疗前，癌症恶病质和体重下降是与淋巴瘤患者不良预后相关的独立因素
Cancer cachexia and weight loss prior to CAR T-cell therapy for lymphoma are independently associated with poor outcomes
第一作者：Valtis YK
Blood Adv (IF=7.4). 2024 Oct 29:bloodadvances.2024014555.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024014555/525819/Cancer-cachexia-and-weight-loss-prior-to-CAR-T
09
新型药物时代弥漫性大B细胞淋巴瘤患者的治疗方案序贯顺序探讨
Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs
第一作者：Karsten IE
Br J Haematol (IF=5.1). 2024 Oct 28.
全文网址：https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19860
10
CAR-T细胞治疗在中枢神经系统淋巴瘤中的应用
CAR T-cell Therapy for Central Nervous System Lymphoma
第一作者：Houillier C
Curr Oncol Rep (IF=4.7). 2024 Oct 28.
全文网址：https://link.springer.com/article/10.1007/s11912-024-01609-3
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.11-1 valid until 2026.11
供稿与审核：临床开发与医学部